Chronic Kidney Disease Treatment Market Expected to Reach $47.9 Billion by 2032—Allied Market Research

According to a new report published by Allied Market Research, titled, “Chronic kidney disease treatment Market," The chronic kidney disease treatment market size was valued at $32 billion in 2022, and is estimated to reach $47.9 billion by 2032, growing at a CAGR of 4% from 2023 to 2032.

Chronic kidney disease encompasses various conditions that inflict damage upon the kidneys, leading to a diminished capacity to effectively filter waste materials from the bloodstream, thereby compromising overall health. This prevalent ailment is frequently associated with the natural aging process, though it can affect individuals of any background. However, it exhibits a higher incidence among individuals of south Asian descent. The diagnosis of chronic kidney disease treatment primarily relies on blood and urine tests, which analyze the presence of elevated levels of specific substances in these bodily fluids. Such indicators serve as clear indications that the kidneys are not functioning optimally. 

The major factors driving the growth of the chronic kidney disease treatment industry include rise in R&D activities for the launch of novel drugs and improvement in existing drugs. Moreover, the rise in the number of approvals from government regulatory institutes is creating lucrative opportunities for the chronic kidney disease treatment market. For instance, in April 2021, AstraZeneca, a global leading life science company, received approval from the U.S. FDA for Farxiga, a prescription medicine approved to reduce the risk of further worsening of initial stage kidney disease to end-stage kidney disease. In addition, The increase in investment in research and development (R&D) activities has a significant impact on the demand for chronic kidney disease (CKD) drugs, creating lucrative opportunities for market growth. R&D plays a crucial role in the development of innovative drugs and therapies, which are essential in addressing the complex nature of chronic kidney disease and improving patient outcomes. 

Furthermore, investments in R&D lead to advancements in drug discovery, formulation, and treatment options for CKD patients. Pharmaceutical companies, academic institutions, and research organizations are actively investing in R&D to explore new therapeutic targets, develop more effective drugs, and enhance existing treatment modalities. This increased focus on R&D activities is driven by the growing prevalence of CKD worldwide and the need for better treatment options. 

Additionally, adoption of modern lifestyles characterized by sedentary habits, unhealthy diets, and high-stress levels have contributed to a rise in the incidence of CKD and its related conditions such as diabetes and hypertension. Unhealthy lifestyle choices, including a lack of physical activity and the consumption of processed foods high in salt, sugar, and saturated fats, have become prevalent in many populations. These lifestyle factors significantly contribute to the development and progression of CKD. As a result, there is a growing demand for chronic kidney disease treatment market trends to manage CKD and its complications. 

However, side effects due to the treatments and expensive cost of dialysis are causing restrain in the market growth. Dialysis is a common treatment for CKD patients, but its high cost creates financial burdens for individuals and healthcare systems alike. The substantial expenses related to dialysis can limit access to treatment and negatively impact the demand for CKD drugs. 

The chronic kidney disease treatment market analysis is segmented on the basis of treatment type, end user, and region. On the basis of treatment type, the market is divided into ACE inhibitors, calcium channel blockers, beta blockers, diuretics, and others. The dialysis segment occupied the highest chronic kidney disease treatment market share in 2022 and is expected to remain dominant during the forecast period owing to rising prevalence of CKD, advancements in dialysis technology, improved healthcare infrastructure, and increased accessibility to reimbursement policies. However, the drugs segment is projected to register the highest CAGR during the forecast period. The advancements, including the introduction of new drugs and therapies, contribute significantly to the growth of the chronic kidney disease treatment market. Further, the availability of a diverse range of drug classes helps healthcare professionals tailor treatment plans to individual patient needs, driving improved outcomes and chronic kidney disease treatment industry.

By end user, the market is classified into hospitals, dialysis centers, ambulatory surgical centers, and others. The hospitals segment dominated the market in 2022 and is expected to remain dominant throughout the chronic kidney disease treatment market forecast. This is attributed to the growth as it is a primary healthcare provider and is often equipped with specialized departments and facilities dedicated to the diagnosis, treatment, and management of CKD. 

North America dominated the chronic kidney disease treatment market share in 2022 and is expected to continue the trend throughout the forecast period. This is attributed to the rise in prevalence of CKD, presence of key players, and availability of high-quality healthcare system & modern medical technologies. However, Asia-Pacific is expected to register the highest CAGR during the forecast period, owing to the presence of a large patient population, growth in awareness about potential of chronic kidney disease treatment, and increase in healthcare funding. 

Key findings of the study  

On the basis of treatment, the drugs segment dominated the chronic kidney disease treatment market size in 2022.  

On the basis of end user, the hospital segment dominated the chronic kidney disease treatment market size  in 2022.  

On the basis of region, North America dominated the market in 2022. However, Asia-Pacific is expected to be the fastest growing region during the forecast period.